ReNerve Limited – Quarterly Activities Report for the Period Ended 31 December 2024

Highlights:
• ReNerve Limited (“ReNerve” or “the Company”) commenced trading on the ASX on 26 November 2024
following a heavily oversubscribed initial public offering, which raised the maximum amount of A$7
million (before costs) at $0.20 per share.
• The Company has achieved strong sales growth. Sales for Q2 FY25 of A$52K represented a 260%
increase on sales for the prior comparable period (PCP) (Q2 FY24). Preliminary unaudited sales for
1H FY25 of A$102K represent a 167% increase on the PCP.
• ReNerve continues to focus on expanding sales of its NervAlign® Nerve Cuff product in its core US
market. In addition, the Company announced sales and marketing agreements for new jurisdictions in
December 2024.
• A clinical study investigating ReNerve’s NervAlign® Nerve Cuff on neurectomies repair is ongoing, with
clinical study data anticipated to be released late in Q3 FY25. The study will focus on post-operative
pain among two cohorts; one treated with the NervAlign® Nerve Cuff and the other without it. ReNerve
has been blinded to the trial.
• On 3 December 2024, ReNerve announced an exclusive distribution agreement with Accession Medical
Supplies Co. for sales and marketing of ReNerve’s primary product, the NervAlign® Nerve Cuff in
Hong Kong and Macau.
• On 12 December 2024, ReNerve partnered with Union MediScience B.S.C. in an exclusive distribution
agreement for the sales and marketing of the NervAlign® Nerve Cuff in the Middle East. The
agreement covers Bahrain, Saudia Arabia, Kuwait, UAE/Dubai and Qatar.
• ReNerve had a strong cash position of $6.4 million at 31 December 2024.